Congenital Adrenal Hyperplasia - How to Improve the Transition from Adolescence to Adult Life

Abstract

Congenital adrenal hyperplasia (CAH) is caused by a defect in the biosynthesis of cortisol that results in maximal activity of the hypothalamic-pituitary adrenal axis with hyperplasia of the adrenals and hyperandrogenism due to the accumulation of androgen precursors. In the salt-wasting subtype of the disorder, which accounts for appr. 75 % of patients with classical CAH, patients are unable to synthesise sufficient amounts of aldosterone and are prone to life-threatening salt-losing crises, whereas the simple virilising form is predominantly characterized by clitoris hypertrophy and posterior labial fusion. In addition, a non-classical variant can be discerned which in most cases is diagnosed at the time of puberty or early adolescence when hirsutism and menstrual irregularities may occur. The vast majority of CAH patients have 21-hydroxylase deficiency (90 - 95 %). Less common forms, such as 11β-hydroxylase deficiency, will not be discussed in this review.

Unfortunately, a considerable number of CAH patients is lost to regular and competent follow-up once they move out of paediatric care. This is most probably the result of insufficient co-operation between paediatric and adult endocrinologists at the time of transition from adolescence to adulthood. Furthermore, there is a lack of clinical guidance regarding psychosexual development in these patients. In this overview we will focus on special aspects of CAH treatment in adolescence and adulthood, and report on our 10-year experience with a transfer system for endocrine patients from paediatric to internal medical care, known as the “Kieler Modell”. For practical purposes, we here provide charts for follow-up of CAH patients that can be adapted for use in any endocrine outpatient clinic.

Key words

Congenital adrenal hyperplasia - transition - adulthood

References

• 1 Acerini C L, Hughes I A. 21-Hydroxylase deficiency defects and their phenotype. Hughes IA, Clark AJL Adrenal Disease in Childhood. Basel; Karger 2000: 93-111
• 2 Alizai N K, Thomas D F, Lilford R J, Batchelor A G, Johnson N. Feminizing genitoplasty or congenital adrenal hyperplasia: what happens at puberty?.  J Urol. 1999;  161 1588-1591
• 3 Baumann A, Baumann C G. Virilizing adrenocortical carcinoma. Development in a patient with salt-losing congenital adrenal hyperplasia.  JAMA. 1982;  248 3140-3141
• 4 Berenbaum S A, Duck S C, Bryk K. Behavioral effects of prenatal versus postnatal androgen excess in children with 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH).  J Clin Endocrinol Metabol. 2000;  85 727-733
• 5 Berenbaum S A. Cognitive function in congenital adrenal hyperplasia.  Endocrinol Metab Clin North Am. 2001;  30 173-192
• 6 Bornstein S R, Vaudry H. Paracrine and neuroendocrine regulation of the adrenal gland-basic and clinical aspects.  Horm Metab Res. 1998;  30 292-296
• 7 Bornstein S R, Stratakis C A, Chrousos G P. Adrenocortical tumors: recent advances in basic concepts and clinical management.  Ann Intern Med. 1999;  130 759-771
• 8 Bornstein S R, Chrousos G P. Clinical review 104: Adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs.  J Clin Endocrinol Metab. 1999;  84 1729-1736
• 9 Bosinski H AG, Peter M, Bonatz G, Arndt R, Heidenreich M, Sippell W G, Wille R. A higher rate of hyperandrogenic disorders in female-to-male transsexuals.  Psychoneuroendocrinology. 1997 a;  22 361-380
• 10 Bosinski H AG, Schröder I, Peter M, Arndt R, Wille R, Sippell W G. Anthropometrical measurements and androgen levels in males, females, and hormonally untreated female-to-male transsexuals.  Arch Sex Behav. 1997 b;  26 143-157
• 11 Bosinski H AG. Determinanten der Geschlechtsidentität - Neue Befunde zu einem alten Streit.  Sexuologie. 2000 a;  7 96-140
• 12 Bosinski H AG. Frau-zu-Mann-Transsexualismus: Ein biopsychosozialer Erklärungsansatz.  Zeitschrift für Humanontogenetik. 2000 b;  2 69-86
• 13 Bosinski H AG. Psychosexuelle Probleme bei Störungen der somatosexuellen Entwicklung.  Med Gen. 2001;  13 42-45
• 14 Brand M, Schoof E, Partsch C J, Peter M, Hoepffner W, Dörr H G, Sippell W G. Anorexia nervosa in congenital adrenal hyperplasia: long-term follow-up of 4 cases.  Exp Clin Endocrinol Diabet. 2000;  108 430-435
• 15 Carlson A D, Obeid J S, Kanellopoulou N, Wilson R C, New M I. Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment.  J Steroid Biochem Mol Biol. 1999;  69 19-29
• 16 Charmandari E, Hindmarsh P C, Johnston A, Brook C GD. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty.  J Clin Endocrinol Metab. 2001;  86 2701-2708
• 17 Charmandari E, Brook C GD, Hindmarsh P C. Why is management of patients with classical congenital adrenal hyperplasia more difficult at puberty?.  Arch Dis Child. 2002;  86 266-269
• 18 Chase C. Rethinking treatment for ambiguous genitalia.  Pediatric Nursing. 1999;  25 451-455
• 19 Clayton P E, Miller W L, Oberfield S E, Ritzén E M, Sippell W G, Speiser P W. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Paediatric Endocrine Society and the European Society for Paediatric Endocrinology.  J Clin Endocrinol Metabol. 2002;  87 4048-4053
• 20 Diamond M, Sigmundson K. Management of intersexuality. Guidelines for dealing with persons with ambiguous genitalia.  Arch Pediatr Adolesc Med. 1997;  151 1046-1050
• 21 Dittmann R W, Kappes M E, Kappes M H. Sexual behaviour in adolescent and adult females with congenital adrenal hyperplasia.  Psychoneuroendocrinology. 1992;  17 153-170
• 22 Dörr H G, Versmold H AT, Sippell W G, Bidlingmaier F, Knorr D. Antenatal betamethasone therapy: effects of maternal, fetal, and neonatal mineralocorticoids, glucocorticoids and progestins.  J Pediatr. 1986;  108 990-993
• 23 Dörr H G, Sippell W G, Willig R P. Pränatale Diagnose und Therapie des adrenogenitalen Syndroms mit 21-Hydroxylase-Defekt. Stellungnahme der Arbeitsgemeinschaft für Pädiatrische Endokrinologie.  Monatsschr Kinderheilkd. 1992;  140 661-663
• 24 Dörr H G, Sippell W G. Prenatal dexamethasone treatment in pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency: effect on midgestational amniotic fluid steroid levels.  J Clin Endocrinol Metab. 1993;  76 117-120
• 25 Dressendorfer R A, Strasburger C J, Bidlingmaier F, Klug I, Kistner A, Siebler T, Kiess W. Development of a highly sensitive nonisotopic immunoassay for the determination of salivary 17-hydroxyprogesterone: reference ranges throughout childhood and adolescence.  Pediatr Res. 1998;  44 650-655
• 26 Edwards C R, Benediktsson R, Lindsay R S, Seckl J R. 11 beta-hydroxysteroid dehydrogenase: key enzymes in determining tissue-specific glucocorticoid effects.  Steroids. 1996;  61 263-269
• 27 Ehrhart-Bornstein M, Hinson J P, Bornstein S R, Scherbaum W A, Vinson G P. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis.  Endocr Rev. 1998;  19 101-143
• 28 Esteban E V, Loughlin T, Yergey A L, Zawadzki J K, Booth J D, Winterer J C, Loriaux D L. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry.  J Clin Endocrinol Metab. 1991;  72 39-45
• 29 Ferriman D, Gallwey J D. Clinical assessment of body hair growth in women.  J Clin Endocrinol. 1961;  21 1440-1447
• 30 Frisch H, Battelino T, Schober E, Baumgartner-Parzer S, Nowotny P, Vierhapper H. Salt wasting in simple virilizing congenital adrenal hyperplasia.  J Pediatr Endocrinol Metab. 2001;  14 1649-1655
• 31 Girgis R, Winter J S. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia.  J Clin Endocrinol Metab. 1997;  82 3926-3929
• 32 Glenn J F, Boyce W H. Adrenogenitalism with testicular adrenal rests simulating interstitial cell tumor.  J Urol. 1963;  89 457-463
• 33 Guo C Y, Weetman A P, Eastell R. Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia.  Clin Endocrinol (Oxf). 1996;  45 535-541
• 34 Gussinye M, Carrascosa A, Potau N, Enrubia M, Vicens-Calvet E, Ibanez L, Yeste D. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia.  Pediatrics. 1997;  100 671-674
• 35 Hennig J, Kieferdorf P, Moritz C, Huwe S, Netter P. Changes in cortisol secretion during shiftwork: implications for tolerance to shiftwork?.  Ergonomics. 1998;  41 610-621
• 36 ISNA (Intersex Society of North America) .Recommendations for treatment: Intersexed infants and children. Pamphlet, 1995, available via www.isna.org (last access date May 26 2004). 
• 37 Jaaskelainen J, Voutilainen R. Long-term outcome of classical 21-hydroxylase deficiency: diagnosis, complications and quality of life.  Acta Paediatr. 2000;  89 183-187
• 38 Jaaskelainen J, Tiitinen A, Voutilainen R. Sexual function and fertility in adult females and males with congenital adrenal hyperplasia.  Horm Res. 2001;  56 73-80
• 39 Jaresch S, Kornely E, Kley H K, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia.  J Clin Endocrinol Metab. 1992;  74 685-689
• 40 Kerrigan J R, Veldhuis J D, Leyo S A, Iranmanesh A, Rogol A D. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis.  J Clin Endocrinol Metab. 1993;  76 1505-1510
• 41 Kim I, Young R H, Scully R E. Leydig cell tumors of the testis: A clinopathological analysis of 40 cases and review of the literature.  Am J Surg Pathol. 1985;  9 177-192
• 42 Krege S, Walz K H, Hauffa B P, Körner L, Rubben H. Long-term follow-up of female patients with congenital adrenal hyperplasia from 21-hydroxylase deficiency, with special emphasis on the results of vaginoplasty.  Acta Obstset Gynecol Scand. 2000;  79 687-692
• 43 Krone N, Roscher A A, Schwarz H P, Braun A. Comprehensive analytical strategy for mutation screening in 21-hydroxylase deficiency.  Clin Chem. 1998;  44 2075-2082
• 44 Krone N, Braun A, Roscher A A, Knorr D, Schwarz H P. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany.  J Clin Endocrinol Metab. 2000;  85 1059-1065
• 45 Krone N, Wachter I, Stefanidou M, Roscher A A, Schwarz H P. Mothers with congenital adrenal hyperplasia and their children: outcome of pregnancy, birth and childhood.  Clin Endocrinol. 2001;  55 523-529
• 46 Krüger C, Höper K, Weissörtel R, Hensen J, Dörr H G. Value of direct measurement of active renin concentrations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  Eur J Pediatr. 1996;  155 858-861
• 47 Kuhnle U, Chow D, Rapaport R, Pang S, Levine L S, New M I. The 21-hydroxylase activity in the glomerulosa and fasciculata of the adrenal cortex in congenital adrenal hyperplasia.  J Clin Endocrinol Metab. 1981;  52 534-544
• 48 Kuhnle U, Bullinger M, Schwarz H P, Knorr D. Partnership and sexuality in adult female patients with congenital adrenal hyperplasia. First results of a cross-sectional quality-of-life evaluation.  J Steroid Biochem Mol Biol. 1993;  45 123-126
• 49 Latronico A C, Chrousos G P. Extensive personal experience: adrenocortical tumors.  J Clin Endocrinol Metab. 1997;  82 1317-1324
• 50 Lightner E S, Levine L S. The adrenal incidentaloma. A pediatric perspective.  Am J Dis Child. 1993;  147 1274-1276
• 51 Lo J C, Grumbach M M. Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia.  Endocrinol Metab Clin North Am. 2001;  1 207-229
• 52 Merke D P, Chrousos G P, Eisenhofer G, Weise M, Keil M F, Rogol A D, Van Wyk J J, Bornstein S R. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency.  N Engl J Med. 2000;  343 1362-1368
• 53 Meyer-Bahlburg H FL. Gender change from female to male in classical CAH.  Horm Behav. 1996;  30 319-332
• 54 Meyer-Bahlburg H FL. Psychobiological models of psychosexual differentiation.  Zschr Humanontogenetik. 2001 a;  3 49-53
• 55 Meyer-Bahlburg H F. Gender and sexuality in classic congenital adrenal hyperplasia.  Endocrinol Metab Clin North Am. 2001 b;  30 155-171
• 56 Moeller H. Chronopharmacology of hydrocortisone and 9 alpha-fluorhydrocortisone in the treatment for congenital adrenal hyperplasia.  Eur J Pediatr. 1985;  144 370-373
• 57 Nass R, Baker S. Androgen effects on cognition: congenital adrenal hyperplasia.  Psychoneuroendocrinology. 1991;  16 189-201
• 58 Nass R, Heier L, Moshang T, Oberfield S, George A, New M I, Speiser P W. Magnetic resonance imaging in the congenital adrenal hyperplasia population: increased frequency of white-matter abnormalities and temporal lobe atrophy.  J Child Neurol. 1997;  12 181-186
• 59 Partsch C J, Sippell W G, MacKenzie I Z, Aynsley-Green A. The steroid hormonal milieu of the undisturbed human fetus and mother at 16 - 20 weeks gestation.  J Clin Endocrinol Metab. 1991;  73 969-974
• 60 Peter M, Sippell W G, Lorenzen F, Willig R P, Westphal E, Grosse-Wilde H G. Improved test to identify heterozygotes for congenital adrenal hyperplasia without index case examination.  Lancet. 1990;  335 1296-1299
• 61 Premawardhana L D, Hughes I A, Read G F, Scanlon M F. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience.  Clin Endocrinol (Oxf). 1997;  46 327-332
• 62 Proto G, Di Donna A, Grimaldi F, Mazzolini A, Purinan A, Bertolissi F. Bilateral testicular adrenal rest tissue in congenital adrenal hyperplasia: US and MR features.  J Endocrinol Invest. 2001;  24 529-531
• 63 Reincke M, Peter M, Sippell W G, Allolio B. Impairment of 11 beta-hydroxylase but not 21-hydroxylase in adrenal “incidentalomas”.  Eur J Endocrinol. 1997;  136 196-200
• 64 Rich M A, Keating M A. Leydig cell tumors associated with congenital adrenal hyperplasia.  Urol Clin North Am. 2000;  27 519-528
• 65 Riepe F G, Krone N, Viemann M, Partsch C J, Sippell W G. Management of congenital adrenal hyperplasia: results of the ESPE questionnaire.  Horm Res. 2002;  58 196-205
• 66 Rutgers J L, Young R H, Scully R E. The testicular “tumor” of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders.  Am J Surg Pathol. 1988;  12 503-513
• 67 Schaal A K. Anthropometrische Untersuchungen bei jungen Frauen mit Adrenogenitalem Syndrom. Kiel: Dissertation Med. Fak. CAU Kiel. 2002 submitted
• 68 Schindler A E, Schindler E M. Gynäkologische Endokrinologie. Reinwein D, Benker G Klinische Endokrinologie und Diabetologie. 2nd ed. Stuttgart; Schattauer 1992: 336-339
• 69 Sinforiani E, Livieri C, Mauri M, Bisio P, Sibilla L, Chiesa L, Martelli A. Cognitive and neuroradiological findings in congenital adrenal hyperplasia.  Psychoneuroendocrinology. 1994;  19 55-64
• 70 Sippell W G, Peter M, Partsch C J. Substitutionstherapie mit Gluko- und Mineralokortikoiden im Kindes- und Jugendalter. Schulte H, Benker G, Allolio B Therapie mit Glukokortikoiden: Molekularbiologische, pharmakologische und klinische Aspekte. Stuttgart; Schattauer 1993: 81-97
• 71 Sippell W G. Erkrankungen der Nebennierenrinde. Lentze MJ, Schaub J, Schulte FJ, Spranger J Pädiatrie. 2nd ed. Berlin, Heidelberg, New York; Springer 2003: 535-549
• 72 Speiser P W, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna M T, Lesser M, New M I, White P C. Disease expression and molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well-definded population.  J Clin Invest. 1992;  90 584-595
• 73 Speiser P W. Congenital adrenal hyperplasia: transition from childhood to adulthood.  J Endocrinol Invest. 2001;  24 681-691
• 74 Srikanth M A, West B R, Ishitani M, Isaacs H, Applebaum H, Costi G. Benign testicular tumors in children with congenital adrenal hyperplasia.  J Pediatr Surg. 1992;  27 639-641
• 75 Stikkelbroeck N M, Otten B J, Pasic A, Jager G J, Sweep C G, Noordam K, Hermus A R. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia.  J Clin Endocrinol Metab. 2001;  86 5721-5728
• 76 Van Wyk J J, Gunther D F, Ritzén M, Wedell A, Cutler Jr G B, Migeon C J, New M I. The use of adrenalectomy as a treatment for congenital adrenal hyperplasia.  J Clin Endocrinol Metab. 1996;  81 3180-3190
• 77 Wachter I, Stefanidou M, Knorr D, Schwarz H P. Gynecologic implications of the adrenogenital syndrome in adolescent and adult women.  Geburtsh Frauenheilk. 1999;  59 616-621
• 78 Walker B R, Skoog S J, Winslow B H, Canning D A, Tank E S. Testis sparing surgery for steroid unresponsive testicular tumors of the adrenogenital syndrome.  J Urol. 1997;  157 1460-1463
• 79 Weitze C, Osburg S. Transsexualism in Germany: Empirical data on epidemiology and application of the German transsexuals' act during its first ten years.  Arch Sex Behav. 1996;  25 409-425
• 80 White P C, Mune T, Agarwal A K. 11 β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess.  Endocr Rev. 1997;  18 135-156
• 81 White P C, Speiser P W. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  Endocrine Revies. 2000;  21 245-291
• 82 Zucker K J, Bradley S J, Oliver G, Blake J, Fleming S, Hood J. Psychosexual development of women with congenital adrenal hyperplasia.  Horm Behav. 1996;  30 300-318